Target Name: SDHDP1
NCBI ID: G100289186
Review Report on SDHDP1 Target / Biomarker Content of Review Report on SDHDP1 Target / Biomarker
SDHDP1
Other Name(s): succinate dehydrogenase complex subunit D pseudogene 1 | Succinate dehydrogenase complex, subunit D, integral membrane protein pseudogene 1

SDHDP1: A Potential Drug Target and Biomarker

Sodium-dependent hexokinase (SDHDP1) is a protein that is expressed in various tissues and cells in the body. It plays a crucial role in the metabolism of glucose, which is one of the most significant substrates for this enzyme. SDHDP1 is a member of the hexokinase family, which includes six structurally similar enzymes that catalyze the reversible reaction of hexokinetic and phosphate groups to form a phosphoryl group and a hexokinetic group, respectively.

SDHDP1 is expressed in various tissues, including the brain, heart, liver, and muscle. It is also highly expressed in the placenta, which is a vital organ that supports the development and growth of new organisms. The primary function of SDHDP1 is to catalyze the metabolism of glucose, which is a key energy source for the cell.

SDHDP1 has been shown to play a crucial role in the regulation of glucose metabolism. It is a key enzyme in the glycolytic pathway, which is the first step in the metabolism of glucose. During glycolytic acidosis, SDHDP1 catalyzes the reversible reaction of hexokinetic and phosphate groups to form a phosphoryl group and a hexokinetic group, respectively. This reaction is essential for the efficient breakdown of glucose and the production of ATP, which is the energy currency of the cell.

In addition to its role in glucose metabolism, SDHDP1 has also been shown to play a crucial role in the regulation of cellular processes. For example, it has been shown to be involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. SDHDP1 has also been shown to play a role in the regulation of cell proliferation, which is the process by which cells grow and divide.

The potential drug targets for SDHDP1 are numerous. For example, SDHDP1 has been shown to be a useful target for the treatment of various metabolic disorders, including diabetes. By inhibiting the activity of SDHDP1, it is possible to lower the levels of glucose in the blood and improve insulin sensitivity. This could make it an effective treatment for diabetes, which is a disease that affects millions of people worldwide.

In addition to its potential as a drug target, SDHDP1 has also been shown to be a useful biomarker for the diagnosis and monitoring of various metabolic disorders. For example, SDHDP1 has been shown to be elevated in the blood of individuals with type 2 diabetes, which is a common form of diabetes. This increase in SDHDP1 levels could be used as a diagnostic marker for this disease. Similarly, SDHDP1 levels have also been shown to be elevated in the blood of individuals with other metabolic disorders, such as obesity and non-alcoholic fatty liver disease (NAFLD). This increase in SDHDP1 levels could be used as a biomarker for these disorders.

In conclusion, SDHDP1 is a protein that plays a crucial role in the metabolism of glucose and the regulation of various cellular processes. Its potential drug targets and biomarkers make it an attractive target for researchers and clinicians who are seeking new treatments for various metabolic disorders. Further research is needed to fully understand the role of SDHDP1 in glucose metabolism and its potential as a drug target and biomarker.

Protein Name: Succinate Dehydrogenase Complex Subunit D Pseudogene 1

The "SDHDP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDHDP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SDHDP2 | SDK1 | SDK1-AS1 | SDK2 | SDR16C5 | SDR16C6P | SDR39U1 | SDR42E1 | SDR42E2 | SDR9C7 | SDS | SDSL | SEBOX | SEC11A | SEC11B | SEC11C | SEC13 | SEC14L1 | SEC14L1P1 | SEC14L2 | SEC14L3 | SEC14L4 | SEC14L5 | SEC14L6 | SEC16A | SEC16B | SEC1P | SEC22A | SEC22B | SEC22C | SEC23A | SEC23B | SEC23IP | SEC24A | SEC24AP1 | SEC24B | SEC24B-AS1 | SEC24C | SEC24D | SEC31A | SEC31B | SEC61A1 | SEC61A2 | SEC61B | SEC61G | SEC62 | SEC63 | SEC63P2 | SECISBP2 | SECISBP2L | SECTM1 | Segment polarity protein dishevelled homolog | SEH1L | SEL1L | SEL1L2 | SEL1L3 | SELE | SELENBP1 | SELENOF | SELENOH | SELENOI | SELENOK | SELENOKP1 | SELENOM | SELENON | SELENOO | SELENOOLP | SELENOP | Selenoprotein | SELENOS | SELENOT | SELENOV | SELENOW | SELL | SELP | SELPLG | SEM1 | SEM1P1 | SEMA3A | SEMA3B | SEMA3B-AS1 | SEMA3C | SEMA3D | SEMA3E | SEMA3F | SEMA3G | SEMA4A | SEMA4B | SEMA4C | SEMA4D | SEMA4F | SEMA4G | SEMA5A | SEMA5A-AS1 | SEMA5B | SEMA6A | SEMA6A-AS1 | SEMA6A-AS2 | SEMA6B | SEMA6C